Myasthenia Gravis Market Value to Reach US$2,313.1 Million by the End of 2025: Transparency Market Research

Global Myasthenia Gravis Market: Research for Introduction of Novel Therapeutics to Play Key Role in Growth, finds TMR

News provided by

Dec 05, 2017, 04:30 ET

ALBANY, New York, December 5, 2017 /PRNewswire/ --

Despite a largely consolidated vendor landscape with several large players and a few regional players, competition in the global myasthenia gravis market is stiff. In this scenario, key players hold small market shares. Alexion Pharmaceutical Inc., Avadel Pharmaceuticals plc, CSL Behring, Grifols S.A., Baxter International Inc., Shire plc, Novartis AG, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, and Valeant Pharmaceuticals International Inc. are to name some prominent companies in the global myasthenia gravis market. These companies are focused on research and development for novel therapeutics for myasthenia gravis. This is one of the key strategic moves adopted by companies operating in the myasthenia gravis market. Further, clinical trials to introduce affordable therapeutics is also an important growth strategy of these companies.

According to a research report by Transparency Market Research (TMR), the global myasthenia gravis market is anticipated to be worth US$2,313.1 mn by the end of 2025 from a valuation of US$975.1 mn in 2016. During the forecast period of 2017 and 2025, the global myasthenia gravis market is projected to clock a CAGR of 10.1%. The key treatment segments include cholinesterase inhibitors, monoclonal antibodies, and chronic Immunomodulators. Among the key regional segments, North America has emerged as a key market for myasthenia gravis on account of a considerable prevalence of myasthenia gravis in the U.S.

View Report at https://www.transparencymarketresearch.com/myasthenia-gravis-market.html

Need to Prevent Deterioration of Life Quality due to Myasthenia Gravis Benefits Market

The rising prevalence of myasthenia gravis that can impact life quality is primarily driving the myasthenia gravis market. Myasthenia gravis is an autoimmune disorder and neuromuscular disorder that causes muscle weakness. The condition is characterized by fatigability and weakness of skeletal muscles, wherein development follows respite. Muscles which are usually impacted are the ones that monitor swallowing and breathing, eye movement, eye lids, and shoulder and facial muscles. The condition affects muscles that a person can control consciously. The weakness of muscles worsens with movement and improves with rest.

Request to View Sample Copy of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26105

In myasthenia gravis, the muscle cells have difficulties to contract and respond to nerve impulses which results in weakness of muscles.

Myasthenia gravis is initiated due to a decline in the number of postsynaptic acetylcholine receptors at neuromuscular joints. This results in reduction of size of neuromuscular end-plate to communicate the nerve signal. In a normal state, acetylcholine is released presynaptically in response to a stimulus resultant in depolarization that results in muscle action. On the other hand, in myasthenia gravis, the number of active postsynaptic receptors may be inadequate to trigger a potential of muscle action. Further, with repeated stimulus, the decline in release of acetylcholine correlates with fatigability.

Request Myasthenia Gravis Market Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26105

Research and Development Initiatives to Fuel Growth

Nevertheless, myasthenia gravis usually does not impact life expectancy. Patients of myasthenia gravis manage their symptoms and lead active lives. The condition is prevalent among people of all ages and ethnicities. Typically, myasthenia gravis is prevalent among men of middle age and among women between 20 to 30 years of age.

Research and development for therapeutics for myasthenia gravis is stoking growth of myasthenia gravis market. Symptomatic and casual treatments are the key therapeutics for myasthenia gravis. The symptomatic treatment involves increasing the duration of presence of acetylcholine, which is responsible for transmitting the nerve impulse by antagonizing acetylcholinesterase.

Global Myasthenia Gravis Market Report is available @ US$ 5795

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]